Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.

Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.


Novartis is the lead EFPIA partner which triggered and contributed to the approval of the HIPPOCRATES consortium under the auspices of Innovative Medicine Initiative 2 (IMI2).

The main in-kind contributions from Novartis are (1) direct involvement of Novartis colleagues in several work packages or working groups corresponding to one full-time equivalent person e.g. an executive team member, a translational medicine expert, a biomarker expert, several global medical affairs colleagues and (2) the INVIGORATE2 study for which Novartis committed to share clinical data from the placebo group (up to the 16-week visit) and samples from the placebo group patients (up to the 16-week visit).

Main contacts

Photo of Christine Huppertz
Christine Huppertz
Photo of Bruno Boutouyrie-Dumont
Bruno Boutouyrie-Dumont
Photo of Rainer Hillenbrand
Rainer Hillenbrand